

Listing of Claims

- 1.-22. (Canceled).
23. (Currently Amended) A method for inhibiting the growth of blood-borne tumors ~~sensitive to thalidomide~~ in a human comprising administering to said human a therapeutically effective amount of thalidomide to inhibit angiogenesis in said tumor.
24. (Canceled).
25. (Previously Presented) The method of Claim 23 wherein the thalidomide is administered orally, sublingually, or buccally.
26. (Previously Presented) The method of Claim 23 wherein the thalidomide is administered in the form of a tablet or capsule.
27. (Previously Presented) The method of Claim 23 wherein the thalidomide is administered in an amount between approximately 0.1 and approximately 300 mg/kg/day.
28. (Previously Presented) The method of Claim 23 wherein the thalidomide is administered in an amount between approximately 0.5 and 50 mg/kg/day.
29. (Previously Presented) The method of Claim 28 wherein the thalidomide is administered in an amount between approximately 1 and approximately 10 mg/kg/day.
30. (Previously Presented) The method of Claim 23 wherein the human is at risk for developing a tumor.
31. (Previously Presented) The method of Claim 23 wherein the thalidomide is administered in the form of a lozenge, a cachet, a solution, a suspension, an emulsion, or a powder.
32. (Canceled).
33. (Previously Presented) The method of Claim 23 wherein the human has a primary tumor.
34. (Previously Presented) The method of Claim 33 wherein the primary tumor is leukemia.

35. (Previously Presented) The method of Claim 33 wherein the thalidomide is administered orally, sublingually, or buccally.

36. (Previously Presented) The method of Claim 33 wherein the thalidomide is administered in an amount between approximately 0.1 and approximately 300 mg/kg/day.

37. (Previously Presented) The method of Claim 36 wherein the thalidomide is administered in an amount between approximately 0.5 and approximately 50 mg/kg/day.

38. (Previously Presented) The method of Claim 37 wherein the thalidomide is administered in an amount between approximately 1 and approximately 10 mg/kg/day.

39. (Previously Presented) The method of Claim 33 wherein the thalidomide is administered in the form of a tablet or capsule.

40. (Previously Presented) The method of Claim 33 wherein the thalidomide is administered in the form of a lozenge, a cachet, a solution, a suspension, an emulsion, or a powder.

41. -58. (Canceled).

59. (Previously Presented) The method of Claim 23 wherein the thalidomide is administered rectally, vaginally, transdermally, topically, basally, or parenterally.

60. (Previously Presented) The method of Claim 23 wherein the thalidomide is administered in the form of an aerosol, a spray, a suppository, a tampon, a pessary, a pastille, an ointment, a cream, a paste, a foam or a gel.

61. (Previously Presented) The method of Claim 33 wherein the thalidomide is administered rectally, vaginally, transdermally, topically, basally, or parenterally.

62. (Previously Presented) The method of Claim 33 wherein the thalidomide is administered in the form of an aerosol, a spray, a suppository, a tampon, a pessary, a pastille, an ointment, a cream, a paste, a foam or a gel.

63.-70. (Canceled)

71. (Previously Presented) The method of Claim 25 or 35, wherein the thalidomide is administered orally.

72. (Previously Presented) The method of Claim 71, wherein the thalidomide is administered in the form of a capsule.